Tag:

Medicare Advantage

Health

Medicare Advantage Auto-Enrollment Under Review by CMS | STAT+

by Chief Editor
written by Chief Editor

The Future of Medicare: Automatic Enrollment and the Rise of Managed Care

The debate over the future of Medicare is intensifying, with a potential shift towards automatic enrollment in Medicare Advantage plans gaining traction. Chris Klomp, President Trump’s Medicare director, recently revealed that the Centers for Medicare & Medicaid Services (CMS) is exploring the feasibility of automatically enrolling beneficiaries in either Medicare Advantage or accountable care organizations (ACOs). Currently, those who don’t actively choose a plan default to traditional Medicare.

What’s Driving the Push for Automatic Enrollment?

The core argument behind automatic enrollment centers on fostering stronger, more proactive healthcare relationships. Klomp suggests that a default enrollment in a managed care setting could lead to “a long-term, secular relationship between the beneficiary, the patient, and their provider.” This contrasts with the current system, where individuals may not actively engage with their healthcare until a need arises.

This consideration aligns with ideas presented in the conservative Project 2025 policy blueprint, signaling a potential broader ideological push towards managed care within Medicare. The goal is to move beyond a fee-for-service model and incentivize preventative care and coordinated health management.

Medicare Advantage: A Growing Force

Medicare Advantage plans, offered by private insurers, are already a significant part of the Medicare landscape. They often include extra benefits not covered by traditional Medicare, such as vision, dental, and hearing care. However, concerns exist regarding potential limitations in provider networks and prior authorization requirements.

The potential for automatic enrollment could dramatically increase the number of beneficiaries in Medicare Advantage. This would have significant implications for insurers, providers, and beneficiaries alike. UnitedHealth, a major player in the Medicare Advantage market, is already facing challenges as it enters 2026 with a smaller business, indicating a complex and evolving market.

Challenges and Concerns Remain

Whereas proponents argue automatic enrollment could improve care coordination and outcomes, critics raise concerns about limiting beneficiary choice. Individuals would still have the option to opt out, but the default setting could disproportionately affect those who are less informed or engaged in their healthcare decisions.

Recent regulatory changes have also highlighted ongoing scrutiny of Medicare Advantage plans. A federal judge recently vacated a rule that would have increased audits of these plans, potentially impacting oversight and accountability. CMS has delayed a rule requiring insurers to remind members of unused benefits, raising questions about ensuring beneficiaries fully utilize their coverage.

The Role of Accountable Care Organizations (ACOs)

Alongside Medicare Advantage, ACOs represent another potential default enrollment option. ACOs are groups of doctors, hospitals, and other healthcare providers who voluntarily work together to deliver coordinated, high-quality care to their Medicare patients. The Medicare Shared Savings Program incentivizes ACOs to reduce healthcare costs while improving patient outcomes.

Choosing ACOs as a default option could emphasize care coordination and preventative services, potentially aligning with the goals of improving long-term health management.

Frequently Asked Questions

What is Medicare Advantage? Medicare Advantage plans are offered by private companies approved by Medicare. They provide all Medicare Part A and Part B benefits and often include extra benefits.

What is an Accountable Care Organization (ACO)? An ACO is a group of doctors, hospitals, and other healthcare providers who voluntarily work together to deliver coordinated care to Medicare patients.

Would I be able to switch back to traditional Medicare if automatically enrolled? Yes, individuals would still have the option to opt out of the automatically assigned plan and choose a different Medicare arrangement.

What is Project 2025? Project 2025 is a conservative policy blueprint outlining a vision for the next presidential administration, including proposals related to healthcare reform.

What does it mean if CMS delays a rule? A delay means the rule will not be implemented on the originally scheduled date, giving stakeholders more time to prepare or allowing CMS to reconsider the policy.

Did you know? Enrollment in Medicare Advantage plans has been steadily increasing over the past decade, now covering over half of all Medicare beneficiaries.

Pro Tip: Regularly review your Medicare options during the annual enrollment period to ensure you have the coverage that best meets your needs.

Stay informed about the evolving landscape of Medicare. Explore CMS.gov for official updates and resources.

0 comments
0 FacebookTwitterPinterestEmail
Health

Medicare Advantage: Enrollment Trends, Plan Terminations & 2026 Outlook

by Chief Editor
written by Chief Editor

Medicare Advantage: Navigating a Shifting Landscape

After years of rapid growth, the Medicare Advantage (MA) market is entering a period of adjustment. Enrollment continues to climb, surpassing 35 million in early 2026, with over half of eligible beneficiaries now choosing private MA plans over traditional Medicare. However, the pace of expansion is slowing, and beneficiaries are facing a slightly smaller selection of plans than in recent years.

The Slowdown in Growth and Plan Availability

The number of Medicare Advantage prescription drug (MA-PD) plans available to beneficiaries has decreased from 36 in 2024 to 32 in 2026. Even as still higher than in 2022, this decline signals a potential shift in the market. This reduction isn’t uniform; some states are experiencing more significant changes than others. For example, Vermont saw over 90% of its Medicare Advantage enrollees in plans that were terminated at the conclude of 2025.

Despite these changes, the vast majority of beneficiaries – 98.9% – who experienced a plan termination at the end of 2025 still had at least one MA-PD option available in 2026. On average, they had a choice of 25 plans.

Plan Terminations and Insurer Strategies

A notable trend is the increase in plan terminations. Approximately 2.6 million people lost coverage through their MA-PD plan at the end of 2025, affecting 13% of individual MA-PD enrollees – a substantial increase from 6% in 2024. This is partly due to insurers reassessing their offerings in response to changes in Medicare Advantage payments and increased healthcare utilization.

UnitedHealth Group had the largest share of enrollees in terminated plans (20%), while smaller insurers accounted for nearly half (49%) of those affected. Some insurers, like UCare Minnesota and Blue Cross Blue Shield of Michigan, completely withdrew from certain markets. However, other insurers, like Devoted Health, are expanding, demonstrating a dynamic market.

Pro Tip: If your Medicare Advantage plan is being discontinued, explore all available options during the annual enrollment period. Don’t hesitate to contact Medicare directly or work with a licensed insurance agent to find a plan that meets your needs.

The Rural Impact

Medicare Advantage enrollees in rural areas are disproportionately affected by plan terminations. While 14% of all MA-PD enrollees live in rural counties, nearly one in four (23%) of those in terminated plans reside in these areas. This can lead to limited options and potential challenges in accessing care.

In some rural states, like Wyoming, South Dakota, and Idaho, over 60% of Medicare Advantage enrollees were impacted by plan terminations. Rural residents facing plan terminations are more likely to be left with no MA-PD options in 2026.

The Role of Special Needs Plans (SNPs)

Amidst these changes, Special Needs Plans (SNPs) are gaining prominence. These plans cater to individuals with specific health needs or those who are dually eligible for Medicare and Medicaid. The number of SNPs has more than doubled since 2020, indicating a growing focus on specialized care.

Financial Considerations and Rebates

Despite concerns from the insurance industry regarding Medicare Advantage payment changes, rebate payments to plans are expected to reach a record high in 2026, averaging over $2,600 per enrollee. These rebates must be used to lower cost-sharing, fund extra benefits, and reduce premiums.

Virtually all Medicare Advantage plans (98%) offer vision, dental, and hearing coverage – benefits not typically included in traditional Medicare. However, the expansion of extra benefits, such as over-the-counter allowances and post-hospital meals, has stalled.

What Happens if Your Plan Terminates?

Beneficiaries whose MA-PD plans are terminated have several options. They can enroll in another Medicare Advantage plan, return to traditional Medicare, or, in some cases, qualify for a special enrollment period to purchase a Medigap policy. Switching to traditional Medicare requires a separate prescription drug plan and may involve higher out-of-pocket costs but offers broader provider access and less utilization management.

Did you know? If you return to traditional Medicare after being in a Medicare Advantage plan, you have a guaranteed issue right to purchase a Medigap policy, meaning insurers cannot deny you coverage or charge you a higher premium due to pre-existing conditions.

Frequently Asked Questions

  • What is Medicare Advantage? Medicare Advantage plans are offered by private companies approved by Medicare and provide Part A and Part B benefits.
  • What is a MA-PD plan? A Medicare Advantage Prescription Drug plan combines medical, hospital, and prescription drug coverage into one plan.
  • What happens if my Medicare Advantage plan is discontinued? You can enroll in another MA-PD plan or return to traditional Medicare.
  • Are there any extra benefits with Medicare Advantage? Many plans offer extra benefits like vision, dental, and hearing coverage.
  • What are SNPs? Special Needs Plans cater to individuals with specific health needs or dual eligibility for Medicare and Medicaid.

This evolving landscape requires careful consideration and proactive planning. Beneficiaries should regularly review their options and choose a plan that best aligns with their individual healthcare needs and preferences.

Explore More: Learn more about your Medicare health plan options on the official Medicare website.

0 comments
0 FacebookTwitterPinterestEmail
Health

Medicare Advantage: $76B Surplus & Industry Pushback on Oversight

by Chief Editor
written by Chief Editor

Medicare Advantage: A $76 Billion Surplus and a Looming Political Battle

The federal government is on track to spend 14% more to cover individuals enrolled in Medicare Advantage (MA) plans compared to those in traditional Medicare – a staggering $76 billion surplus directed towards health insurance companies, according to a recent report by the Medicare Payment Advisory Commission (MedPAC).

The Growing Gap in Payments

This significant financial disparity highlights a long-standing issue: consistent overpayments to MA insurers. MedPAC, an independent body advising Congress on Medicare, has repeatedly pointed out these overpayments. The current $76 billion figure represents a substantial increase, fueling debate about the program’s financial sustainability and fairness.

Industry Pushback and Lobbying Efforts

As scrutiny intensifies, industry groups are actively working to counter MedPAC’s findings and influence policy decisions. Organizations like the Better Medicare Alliance and the Healthcare Leadership Council have criticized MedPAC’s reports and are advocating for increased funding for the program. Their efforts include endorsing editorials questioning MedPAC’s credibility and supporting legislation that could limit the commission’s research capabilities.

The Trump Administration’s Role and Future Outlook

The future of Medicare Advantage funding is closely tied to the current political landscape. The article suggests a potentially favorable environment for MA insurers under the Trump administration, mirroring a trend observed during his first term. Previous administrations, including the Biden administration, have also increased payments to MA plans, though subsequently attempted to address overpayments and care denials.

Coding Practices and Revenue Impacts

Recent government proposals to maintain relatively flat payments for MA plans next year, coupled with changes to coding practices, have caught the health insurance industry off guard. These changes, particularly those addressing “upcoding” – a practice where insurers inflate risk scores to justify higher payments – could significantly impact insurer revenue.

Providers Exiting Medicare Advantage Networks

Concerns about inadequate provider networks are growing, with healthcare providers increasingly leaving MA plans. This trend, alongside plans scaling back benefits and withdrawing from certain areas, raises questions about the long-term viability and quality of care offered through Medicare Advantage.

What is Project 2025 and How Could it Impact Medicare Advantage?

A policy proposal known as Project 2025 aims to build Medicare Advantage the default enrollment option in Medicare and significantly reduce oversight of the program. If implemented, this could accelerate the privatization of Medicare and potentially exacerbate existing overpayment issues.

Did you know?

The Medicare Advantage program is expected to cost taxpayers and beneficiaries over $500 billion this year.

FAQ: Medicare Advantage Overpayments

  • What is Medicare Advantage? Medicare Advantage offers a way to get your Medicare Part A and Part B benefits through a private insurance company.
  • Why are there overpayments to MA plans? Overpayments are attributed to factors like risk adjustment inaccuracies and coding practices.
  • What is MedPAC? The Medicare Payment Advisory Commission is an independent group that advises Congress on Medicare policy.
  • What is upcoding? Upcoding is the practice of inflating risk scores to receive higher payments from Medicare.

Pro Tip: Beneficiaries should carefully compare coverage options and provider networks before enrolling in a Medicare Advantage plan.

Explore more articles on Health Care Inc. to stay informed about the latest developments in Medicare policy.

Have questions about Medicare Advantage? Share your thoughts in the comments below!

0 comments
0 FacebookTwitterPinterestEmail
Health

Medicare Part D Enrollment 2026: MA-PDs Outpace PDPs | KFF

by Chief Editor
written by Chief Editor

Medicare Part D Enrollment Shifts: A Growing Trend Towards Medicare Advantage and Employer-Sponsored Plans

As of February 2026, 56.1 million Medicare beneficiaries are enrolled in Part D prescription drug plans, marking a significant milestone in the program’s evolution. Recent data reveals a notable shift in enrollment patterns, with a growing preference for Medicare Advantage plans (MA-PDs) and employer-sponsored group plans.

The Rise of Medicare Advantage Plans (MA-PDs)

More than half of all Part D enrollees – 56%, or 31.3 million people – are now choosing MA-PDs, which combine medical and prescription drug coverage. This reflects the broader trend of increasing enrollment in Medicare Advantage overall. While MA-PD enrollment saw a slight dip between February 2025 and February 2026, it remains the dominant choice for many beneficiaries.

Pro Tip: If you’re latest to Medicare, carefully compare MA-PDs and stand-alone Prescription Drug Plans (PDPs) to determine which best suits your healthcare needs and budget.

Stand-Alone PDPs: A Modest Increase

Stand-alone PDP enrollment stands at 24.9 million, representing 44% of all Part D enrollees. This is a slight increase from previous years, with overall PDP enrollment growing by 1.7 million between 2025 and 2026. Though, the number of available PDP options continues to decrease, dropping from 14 to 11 for the average beneficiary.

The Unexpected Surge in Employer-Sponsored Plans

A surprising development is the significant increase in enrollment in employer-sponsored group PDPs. Enrollment in these plans jumped by 1.2 million, reaching 6.3 million – the largest increase since 2013. Simultaneously, enrollment in employer-sponsored group MA-PDs decreased by 1.2 million, falling to 2.7 million. This marks the first year-over-year decline in group MA-PD enrollment since 2010.

This shift appears to be driven by a strategic move by employers and unions to separate medical and prescription drug benefits. By contracting separately for MA-only plans and stand-alone PDPs, groups can take advantage of the Part D premium stabilization demonstration and receive additional federal subsidies.

Premium Trends: Lower Costs with PDPs

The average monthly enrollment-weighted premium for non-group PDPs fell from $39 to $36 between February 2025 and February 2026. This is likely due to the availability of lower-premium PDPs, prompting beneficiaries to switch plans. Several national PDPs are now offering premiums below $10 in many regions.

Did you know? Some PDPs are offering premiums well below $10 in many regions, providing affordable options for those in traditional Medicare.

Key Players: Humana and Centene Lead PDP Growth

Humana and Centene experienced the largest increases in PDP enrollment between 2025 and 2026. Humana’s PDP enrollment surged by 61%, while Centene’s increased by 11%. Both companies achieved this growth by reducing monthly premiums and offering low or zero-premium PDP options in several regions.

Conversely, CVS Health and Health Care Service Corporation saw declines in PDP enrollment, while UnitedHealth Group experienced only a modest increase. These companies generally have higher average premiums across their PDP offerings.

Looking Ahead: Potential Future Trends

Several factors suggest these trends will continue in the coming years.

  • Continued Growth of Medicare Advantage: The increasing popularity of MA plans is likely to persist, driven by factors such as convenience, additional benefits, and competitive premiums.
  • Employer-Sponsored Plans as a Growing Segment: The trend of employers and unions shifting to separate MA-only and PDP contracts is expected to continue, fueled by the availability of premium subsidies.
  • Premium Competition: The competition among PDPs will likely intensify, leading to further premium reductions and a wider range of plan options.
  • Consolidation in the Market: The Medicare Part D landscape may see further consolidation as insurance companies seek to gain scale and efficiency.

FAQ

Q: What is Medicare Part D?
A: Medicare Part D helps cover the cost of prescription drugs. It’s offered through private insurance companies approved by Medicare.

Q: What’s the difference between an MA-PD and a PDP?
A: An MA-PD combines medical and drug coverage, while a PDP covers only prescription drugs and is used with Original Medicare.

Q: Can I switch Medicare plans during the year?
A: Generally, you can only switch plans during the Annual Enrollment Period (October 15 – December 7). There are some exceptions, such as if you qualify for a Special Enrollment Period.

Q: Where can I find more information about Medicare Part D?
A: Visit the official Medicare website at https://www.medicare.gov/health-drug-plans/part-d.

Ready to explore your Medicare options? Utilize the Medicare Plan Finder tool on Medicare.gov to compare plans and find the coverage that’s right for you. Share this article with friends and family who may benefit from this information!

0 comments
0 FacebookTwitterPinterestEmail
Health

Health Insurance Markets: Individual, Group, Medicaid & Medicare Advantage Explained

by Chief Editor
written by Chief Editor

Navigating the Shifting Landscape of US Health Insurance Markets

The US health insurance market is a complex ecosystem, encompassing individual, group, Medicaid managed care, and Medicare Advantage plans. Recent shifts in federal subsidies and ongoing debates about the Affordable Care Act (ACA) are creating ripples across these sectors, impacting millions of Americans. Understanding the dynamics of each market is crucial for both consumers and industry stakeholders.

The Individual Market: Subsidy Lapses and Enrollment Trends

The individual market, where people purchase coverage through the ACA’s exchanges or directly from insurers, is particularly sensitive to policy changes. The expiration of enhanced premium subsidies is already showing effects, with enrollment figures declining as costs rise for some. This market serves individuals and families, and includes both ACA-compliant plans and those that aren’t, like grandfathered policies and short-term plans.

The federal government plays a key role through subsidies for low and middle-income individuals and measures like risk adjustment to stabilize insurer finances. Insurers receive premium payments from enrollees, plus any applicable federal subsidies.

Group Market Dynamics: A Majority Remains Self-Funded

The fully insured group market caters to employers and their employees. However, a significant portion – 63% of workers with employer-sponsored insurance as of 2024 – are covered by self-funded plans, which are not included in this analysis. This analysis focuses on the roughly 25 million people covered by fully insured group plans. Plans in this market receive premium payments from both employers and employees.

Medicaid Managed Care: Growth and Variation

Medicaid managed care is a rapidly growing segment, with over 66 million beneficiaries receiving care through comprehensive risk-based managed care organizations (MCOs) as of July 2024 – representing more than three-fourths of all Medicaid beneficiaries nationally. These MCOs contract with state Medicaid programs to deliver care.

However, there’s significant variation across states in terms of covered services. Data collection also presents challenges, with some states having different reporting practices, potentially leading to incomplete data for national analyses. The NAIC defines Medicaid as plans that charge a premium and cover full medical costs, excluding Administrative Services Only (ASO) plans, but other plan types may be included in the data.

Medicare Advantage: Surpassing Traditional Medicare

Medicare Advantage is experiencing substantial growth, covering over half of all Medicare beneficiaries – around 33 million people in 2024. The federal government provides risk-adjusted payments to these private plans, averaging nearly $14,823 per enrollee in 2024, to cover the cost of benefits under Medicare Parts A and B, as well as supplemental benefits like dental, vision, and hearing care. Some plans may also charge enrollees an additional premium.

Did you understand? Medicare Advantage plans often offer benefits beyond traditional Medicare, such as wellness programs and transportation assistance.

Future Trends and Potential Impacts

Several factors suggest continued evolution in these markets. Ongoing debates surrounding the ACA and potential legislative fixes could significantly impact the individual market. The future of enhanced subsidies remains uncertain, and any changes could lead to further enrollment fluctuations.

In the group market, the trend towards self-funding is likely to continue, potentially reducing the size of the fully insured market. The Medicaid managed care sector is expected to grow as states continue to expand Medicaid eligibility. However, ensuring consistent quality of care and addressing variations in covered services will be key challenges.

Medicare Advantage is poised for further expansion, driven by its popularity among beneficiaries and the incentives for plans to attract enrollees. However, concerns about risk selection and the potential for overpayment will likely remain points of discussion.

FAQ

Q: What is the Affordable Care Act (ACA)?
A: The ACA is a comprehensive healthcare reform law enacted in 2010, aimed at increasing health insurance coverage and affordability.

Q: What is Medicaid Managed Care?
A: It’s a system where private organizations (MCOs) deliver healthcare services to Medicaid beneficiaries under contract with state Medicaid programs.

Q: What is Medicare Advantage?
A: It allows Medicare beneficiaries to receive their benefits through private insurance plans.

Q: How do subsidies affect health insurance costs?
A: Subsidies reduce the monthly premium costs for eligible individuals and families, making coverage more affordable.

Pro Tip: Regularly review your health insurance options during open enrollment periods to ensure you have the best plan for your needs and budget.

Wish to learn more about navigating the health insurance landscape? Explore our other articles or subscribe to our newsletter for the latest updates and insights.

0 comments
0 FacebookTwitterPinterestEmail
Health

Medicare Advantage Enrollment 2026: Growth Slows, SNPs Rise – KFF

by Chief Editor
written by Chief Editor
0 comments
0 FacebookTwitterPinterestEmail
Health

Medicare Advantage Enrollment Growth Slows in 2024 | STAT

by Chief Editor
written by Chief Editor

Medicare Advantage Growth Slows: What’s Behind the Shift?

For years, Medicare Advantage (MA) plans have been the fastest-growing part of Medicare. But new data reveals a significant slowdown. As of February 1, enrollment reached 35.5 million, a modest 3% increase from the previous year. This marks a stark contrast to the 7%-10% annual growth seen between 2017, and 2024.

The Recent Enrollment Dip: A Closer Look

The most recent enrollment window, spanning October 15 to December 7, saw only a 1% increase in MA enrollment. This stagnation raises questions about the future trajectory of the program and the factors influencing seniors’ choices.

Why the Slowdown? Regulatory Scrutiny and Plan Performance

Several factors are likely contributing to this shift. Increased scrutiny from Medicare regulators at the Centers for Medicare and Medicaid Services (CMS) is playing a role. CMS has been “looking into allegations” regarding MA plan practices, signaling a potential tightening of regulations.

Recent reporting by STAT and others has highlighted concerns about how Medicare Advantage plans use algorithms to manage patient care. Investigations have revealed that some plans have improperly denied or limited rehabilitation care for older and disabled patients, prioritizing profits over patient needs. This has led to frustration and anger among patients and healthcare providers alike.

The Impact of Risk Adjustment and Upcoding

The Medicare Advantage program relies on a risk adjustment system to compensate plans for enrolling sicker individuals. Still, there have been concerns about “upcoding,” where plans may inflate the risk scores of their enrollees to receive higher payments from the government. Recent efforts by the federal government to use fresher data aim to rein in this practice.

UnitedHealth Group and the Broader Trend

The slowdown isn’t isolated to a single insurer. Even as specific data on individual plan performance requires a STAT+ subscription, the overall trend suggests a broader cooling of MA’s rapid expansion. UnitedHealth Group, the nation’s largest health insurer, is a key player in the Medicare Advantage market and is likely impacted by these changes.

What Does This Mean for the Future of Medicare Advantage?

The slowing growth of Medicare Advantage doesn’t necessarily signal the program’s decline, but it does indicate a potential turning point. Increased regulatory oversight, coupled with greater awareness of potential issues with plan practices, could lead to a more sustainable – and patient-centered – approach to managed care within Medicare.

FAQ

Q: What is Medicare Advantage?
A: Medicare Advantage plans are offered by private companies approved by Medicare. They provide all Medicare Part A and Part B benefits, and often include extra benefits like vision, dental, and hearing care.

Q: What is upcoding?
A: Upcoding is the practice of inflating the risk scores of patients to receive higher payments from Medicare.

Q: Where can I find more information about Medicare Advantage plans?
A: You can find more information on the Medicare website.

Q: What is STAT+?
A: STAT+ is a subscription service offered by STAT News that provides in-depth analysis of the business of health care.

Did you know? Bob Herman of STAT News has been recognized for his in-depth reporting on the business of health care, particularly his coverage of Medicare Advantage.

Pro Tip: During Medicare open enrollment, carefully compare the costs, benefits, and provider networks of different plans before making a decision.

Want to stay informed about the latest developments in health care? Subscribe to the Health Care Inc. Newsletter for expert analysis and insights.

0 comments
0 FacebookTwitterPinterestEmail
Health

Medicare Prior Authorization: DMEPOS, Hospital Services & Ambulance Transport

by Chief Editor
written by Chief Editor

Medicare Prior Authorization: A Growing Trend and What It Means for Patients & Providers

For years, the Centers for Medicare & Medicaid Services (CMS) has been quietly expanding the use of prior authorization – essentially, getting approval before a service is rendered – for a growing list of medical procedures and equipment. What started as a targeted effort to curb unnecessary spending is now evolving into a more sophisticated system, increasingly leveraging technology and data analysis. This isn’t just about saving money; it’s a fundamental shift in how Medicare manages healthcare costs and utilization.

The Expansion of Prior Authorization: A Timeline

The initial push began in 2015 with Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS). Today, over 70 items require prior authorization, including crucial equipment like power mobility devices and prosthetics. This was followed by hospital outpatient services in 2019, targeting procedures often considered cosmetic but sometimes bundled with necessary care – think rhinoplasty or vein ablation. The list has steadily grown to include implanted spinal neurostimulators and even facet joint interventions.

A key turning point came with the success of the Repetitive, Scheduled Non-Emergent Ambulance Transport (RSNAT) Prior Authorization Model. Launched in 2014 and expanded nationwide in 2020, this program demonstrably saved Medicare approximately $650 million over four years. This success story fueled further expansion, proving the model’s potential for cost savings without compromising care.

The WISeR Model: AI and the Future of Prior Auth

The most recent development, the Wasteful and Inappropriate Service Reduction (WISeR) Model launched in January 2026, signals a significant leap forward. Implemented in six states – New Jersey, Ohio, Oklahoma, Texas, Arizona, and Washington – WISeR focuses on services particularly vulnerable to fraud or abuse, such as skin substitutes and orthopedic pain management. Crucially, it explicitly mentions the use of “enhanced technologies, such as artificial intelligence,” to automate and improve the prior authorization process.

Did you know? The WISeR model represents one of the first large-scale applications of AI in Medicare prior authorization, potentially setting a precedent for broader adoption across other services and states.

What’s Driving This Trend? Beyond Cost Savings

While cost containment is a primary driver, several other factors are contributing to the rise of prior authorization. Increased scrutiny of healthcare spending, a growing aging population, and advancements in data analytics all play a role. CMS is increasingly focused on value-based care, aiming to ensure that every dollar spent delivers the best possible outcome for patients.

Furthermore, the ability to identify and prevent fraud, waste, and abuse is a significant benefit. Prior authorization allows CMS to flag potentially inappropriate or unnecessary services, protecting taxpayer dollars and ensuring resources are allocated effectively.

Impact on Patients and Providers: Challenges and Opportunities

The expansion of prior authorization isn’t without its challenges. For patients, it can mean delays in accessing necessary care and increased administrative burden. Providers, particularly smaller practices, often struggle with the complexities of navigating the prior authorization process, leading to administrative costs and potential disruptions in patient care.

However, there are also potential opportunities. The CMS is now offering prior authorization exemptions for suppliers with high affirmation rates (90% or higher), streamlining the process for those consistently providing appropriate care. The use of AI in the WISeR model promises to automate and expedite approvals, reducing administrative burdens for both patients and providers.

Pro Tip: Providers should invest in robust documentation systems and stay up-to-date on the latest CMS guidelines to minimize prior authorization denials and ensure timely patient care.

Looking Ahead: What to Expect in the Next 5-10 Years

The trend towards increased prior authorization is likely to continue. Expect to see:

  • Broader Scope: More services and procedures will likely be added to the prior authorization list, particularly those with high costs or a history of inappropriate utilization.
  • AI Integration: Artificial intelligence will play an increasingly prominent role in automating the prior authorization process, improving efficiency, and reducing errors.
  • Real-Time Decisions: The goal will be to move towards real-time prior authorization decisions, eliminating delays and improving the patient experience.
  • Data-Driven Insights: CMS will leverage data analytics to identify areas where prior authorization can be most effective and to refine the process over time.
  • Increased Focus on Value-Based Care: Prior authorization will be increasingly aligned with value-based care models, incentivizing providers to deliver high-quality, cost-effective care.

FAQ

Q: What is prior authorization?
A: Prior authorization is a process where healthcare providers must obtain approval from an insurance company (in this case, Medicare) before providing a specific service or medication.

Q: Why is Medicare using more prior authorization?
A: Primarily to control costs, prevent fraud, and ensure appropriate utilization of healthcare resources.

Q: How does the WISeR model work?
A: The WISeR model uses prior authorization for select services in six states, and incorporates AI to help review and approve requests.

Q: Will prior authorization delay my access to care?
A: It potentially can, but CMS is working to streamline the process and reduce delays, particularly through the use of AI.

Q: Where can I find a list of services requiring prior authorization?
A: You can find the current list on the CMS website: DMEPOS Prior Authorization List

Reader Question: “I’m a small practice owner. How can I best prepare for these changes?”

A: Invest in staff training, streamline your documentation processes, and consider utilizing technology solutions that can automate prior authorization requests. Staying informed about CMS updates is also crucial.

Want to learn more about Medicare policies and their impact on healthcare? Explore our other articles or subscribe to our newsletter for the latest updates.

0 comments
0 FacebookTwitterPinterestEmail
Health

Trump Adds Physician-Administered Drugs to Medicare Price Negotiation List

by Chief Editor
written by Chief Editor

Medicare Drug Price Negotiation: A Turning Tide for Healthcare Costs?

The recent announcement by the Trump administration – adding 15 drugs to the Medicare price negotiation list, crucially including those administered in doctor’s offices – marks a significant shift in the landscape of pharmaceutical pricing. While framed by the administration as building on voluntary agreements, this move expands a program initially championed by the Biden administration, and signals a potential long-term trend towards greater government intervention in drug costs.

Beyond Part D: The Impact of Including Physician-Administered Drugs

For the first two years of the Medicare negotiation program, focus was solely on drugs dispensed through retail pharmacies (Part D). Expanding negotiation to include drugs administered by physicians (Part B) is a game-changer. This is particularly impactful for treatments like those for cancer and HIV, where costs can be astronomical. However, it also introduces complexities. Unlike Part D, where detailed claims data is readily available, tracking pricing for Part B drugs, especially within Medicare Advantage plans (which cover over half of beneficiaries), is more challenging. This data gap could initially slow the negotiation process and potentially limit savings.

Did you know? Drugs designated as “protected class” – like Biktarvy (HIV) and Verzenio (breast cancer) on the new list – often see smaller rebates from insurers due to mandatory coverage requirements. This makes them prime candidates for substantial discounts through negotiation.

The Political Tightrope: Trump’s Approach and Future Implications

The Trump administration’s approach is noteworthy. While implementing the negotiation program, it simultaneously emphasizes voluntary agreements with drug manufacturers. This strategy attempts to appease both sides – demonstrating action on lowering costs while avoiding direct confrontation with the powerful pharmaceutical lobby. This duality suggests a potential future where negotiation and voluntary agreements coexist, creating a hybrid system. However, the long-term sustainability of voluntary agreements without the leverage of mandatory negotiation remains questionable.

Recent data from the Kaiser Family Foundation (https://www.kff.org/health-policy/medicare-drug-negotiation/) shows that the 20 drugs selected in the first round of negotiations could save Medicare an estimated $20 billion per year. Expanding this to include Part B drugs has the potential to significantly increase those savings.

The Rise of Value-Based Pricing and International Reference Pricing

The move towards negotiation aligns with a broader global trend towards value-based pricing – tying drug prices to their clinical benefit. The Trump administration’s highlighting of voluntary agreements mirroring prices in other developed countries also points towards the growing acceptance of international reference pricing. Countries like Canada and the UK routinely negotiate drug prices, resulting in significantly lower costs compared to the United States.

Pro Tip: Keep an eye on the development of biosimilars. These “generic” versions of biologic drugs offer another avenue for cost savings and increased competition in the pharmaceutical market.

Challenges Ahead: Data Transparency and Implementation

Despite the positive momentum, significant challenges remain. Improving data transparency, particularly within Medicare Advantage plans, is crucial for effective negotiation. The government needs access to accurate pricing information for Part B drugs to ensure fair and equitable negotiations. Furthermore, the implementation of the program will require careful monitoring to prevent unintended consequences, such as drug manufacturers delaying the release of new medications.

The pharmaceutical industry is likely to continue lobbying against broader price controls. Expect legal challenges and potential attempts to undermine the negotiation process. The success of this program will depend on the government’s ability to navigate these obstacles and maintain its commitment to lowering drug costs for Medicare beneficiaries.

The Drugs on the List: A Closer Look

The 15 drugs selected represent a diverse range of conditions, from chronic obstructive pulmonary disease (Anoro Ellipta) to rheumatoid arthritis (Cimzia, Orencia, Xeljanz). The inclusion of Botox, a widely used cosmetic and therapeutic treatment, is particularly noteworthy, potentially impacting a large patient population. The full list includes:

  • Anoro Ellipta, chronic obstructive pulmonary disease. (GlaxoSmithKline)
  • Biktarvy, HIV. (Gilead Sciences)
  • Botox and Botox Cosmetic, several cosmetic and therapeutic uses, including chronic migraines. (AbbVie)
  • Cimzia, rheumatoid arthritis, Crohn’s disease, and other autoimmune conditions. (UCB)
  • Cosentyx, autoimmune conditions including plaque psoriasis. (Novartis)
  • Entyvio, active ulcerative colitis and Crohn’s disease. (Takeda)
  • Erleada, prostate cancer. (Janssen Biotech)
  • Kisqali, breast cancer. (Novartis)
  • Lenvima, advanced cancers. (Eisai)
  • Orencia, rheumatoid arthritis and psoriatic arthritis. (Bristol-Myers Squibb)
  • Rexulti, schizophrenia. (Otsuka Pharmaceuticals)
  • Trulicity, cardiovascular diseases. (Eli Lilly)
  • Verzenio, breast cancer. (Eli Lilly)
  • Xeljanz and Xeljanz XR, rheumatoid arthritis and multiple other inflammatory conditions. (Pfizer)
  • Xolair, asthma and other allergic reactions. (Genentech)

FAQ

Q: When will the negotiated prices take effect?
A: The negotiated prices for the drugs chosen this year will take effect in 2028.

Q: Will this affect all Medicare beneficiaries?
A: Initially, the savings will primarily benefit those in traditional Medicare. The impact on Medicare Advantage plans will depend on how those plans choose to pass on the savings.

Q: What is “international reference pricing”?
A: It’s a practice where a country uses the prices of drugs in other developed nations as a benchmark for its own pricing negotiations.

Q: What are “protected class” drugs?
A: These are drugs that Medicare plans are required to cover, limiting insurers’ ability to negotiate large rebates.

Q: Where can I find more information about the Medicare drug negotiation program?
A: Visit the Centers for Medicare & Medicaid Services (CMS) website: https://www.cms.gov/medicare/prescription-drug-coverage/prescription-drug-price-negotiation

Reader Question: “Will this impact access to new drugs?” This is a valid concern. The negotiation program is designed to lower prices for existing drugs, not to restrict access to new innovations. However, the industry argues that reduced profits could disincentivize research and development. This remains a key point of debate.

Want to stay informed about the latest developments in healthcare policy? Subscribe to our newsletter for regular updates and in-depth analysis. Share your thoughts on this evolving landscape in the comments below!

0 comments
0 FacebookTwitterPinterestEmail
Health

UnitedHealth Accused of Exploiting Medicare Advantage Coding for Profit

by Chief Editor
written by Chief Editor

UnitedHealth’s Coding Practices: A Glimpse into the Future of Medicare Advantage

A recent Senate Judiciary Committee report has thrown a spotlight on UnitedHealth Group’s aggressive tactics in maximizing payments within the Medicare Advantage program. The core issue? How patients are “coded” – the diagnoses listed on their medical records – directly impacts how much money UnitedHealth receives from the government. This isn’t a new practice, but the report suggests UnitedHealth has elevated it to a central profit strategy, raising concerns about the integrity of the program and potentially impacting patient care.

The Risk Adjustment Game: How It Works

Medicare Advantage relies on a system called “risk adjustment.” The idea is simple: insurers get paid more for enrolling sicker patients who require more expensive care. This incentivizes plans to cover individuals with complex health needs. However, the system is only as accurate as the data it receives. Insurers are responsible for submitting accurate diagnosis codes for their members. The Senate report alleges UnitedHealth has been systematically identifying and adding diagnoses to patient records – sometimes retroactively – to inflate their risk scores and, consequently, their payments.

This isn’t necessarily about fraudulent billing in the traditional sense, but rather a highly optimized interpretation of the rules. As Bob Herman of STAT News, who extensively covered this issue, points out, UnitedHealth is simply “pushing risk adjustment tactics to the utmost degree.” The question is whether this aggressive approach is aligned with the original intent of Medicare Advantage.

Beyond UnitedHealth: A Systemic Issue?

While the report focuses on UnitedHealth, the largest player in the Medicare Advantage market, the incentive structure creates a potential for similar practices across the industry. With over half of Medicare beneficiaries now enrolled in Medicare Advantage plans, the financial stakes are enormous. A 2023 report by the Department of Health and Human Services’ Office of Inspector General found widespread coding errors among Medicare Advantage organizations, leading to overpayments.

The core problem isn’t necessarily malicious intent, but the inherent conflict of interest. Insurers are businesses, and maximizing profits is a primary goal. When the rules allow for significant financial gains through coding practices, it’s reasonable to expect companies to exploit those opportunities.

Future Trends: What to Expect

The UnitedHealth report is likely just the beginning. Here’s what we can anticipate in the coming years:

  • Increased Scrutiny: Expect more investigations from both government agencies and the media. The spotlight on Medicare Advantage coding will intensify, leading to greater oversight.
  • Regulatory Changes: The Centers for Medicare & Medicaid Services (CMS) will likely propose changes to the risk adjustment system. These could include stricter auditing procedures, more detailed coding guidelines, and potentially, a shift towards prospective payment models.
  • AI and Automation: Insurers will increasingly leverage artificial intelligence and machine learning to identify potential diagnoses and optimize coding. This could lead to even more accurate (or, conversely, more aggressive) risk scoring.
  • Focus on Data Validation: CMS will likely invest in better data validation tools to identify and correct coding errors. This could involve cross-referencing claims data with electronic health records and other sources.
  • Consolidation Concerns: The report highlights the risks associated with the increasing consolidation of the healthcare industry. UnitedHealth’s massive size gives it significant leverage and resources to navigate complex regulations and optimize its financial performance.

Did you know? The Medicare Advantage program was originally designed to offer seniors more choices and potentially lower costs. However, concerns about coding practices and marketing tactics are raising questions about whether it’s achieving those goals.

The Impact on Patients

While the immediate impact is financial – affecting government spending and insurer profits – there are potential consequences for patients. Inaccurate coding could lead to inappropriate care, delayed access to services, or unnecessary medical interventions. Furthermore, the focus on maximizing risk scores could incentivize insurers to selectively enroll healthier patients, leaving sicker individuals with fewer options.

Pro Tip: Medicare beneficiaries should carefully review their Explanation of Benefits (EOB) statements and question any diagnoses they don’t recognize.

The Role of Technology and Data Analytics

The future of risk adjustment will be heavily influenced by technology. Companies are already using sophisticated data analytics tools to identify patients who may be eligible for additional diagnoses. This raises ethical questions about the appropriate use of data and the potential for bias. For example, algorithms trained on biased data could disproportionately identify diagnoses in certain demographic groups.

The rise of telehealth and remote patient monitoring will also play a role. These technologies generate vast amounts of data that can be used to assess patient risk and inform coding decisions. However, it’s crucial to ensure that this data is accurate, reliable, and used responsibly.

FAQ

  • What is risk adjustment? It’s a system used by Medicare Advantage to pay insurers more for covering sicker patients.
  • Is it illegal for insurers to add diagnoses to patient records? Not necessarily, but it’s subject to scrutiny if it’s done improperly or with the intent to defraud the government.
  • How does this affect me as a Medicare beneficiary? Potentially through changes in your plan’s coverage, access to care, or premiums.
  • What can I do if I suspect inaccurate coding? Review your Explanation of Benefits statements and contact your insurer or Medicare directly.

Reader Question: “Will these changes lead to higher Medicare premiums for beneficiaries?” – This is a valid concern. Increased scrutiny and potential overpayment corrections could lead to adjustments in future premium rates. However, the overall impact will depend on a variety of factors, including CMS’s policy decisions and the performance of Medicare Advantage plans.

Stay informed about these developments. The future of Medicare Advantage – and the financial health of the program – depends on addressing these critical issues.

Explore further: Subscribe to the Health Care Inc. newsletter for in-depth analysis of the business of healthcare.

0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts